160 related articles for article (PubMed ID: 16027731)
1. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
Prentice LM; Shadeo A; Lestou VS; Miller MA; deLeeuw RJ; Makretsov N; Turbin D; Brown LA; Macpherson N; Yorida E; Cheang MC; Bentley J; Chia S; Nielsen TO; Gilks CB; Lam W; Huntsman DG
Oncogene; 2005 Nov; 24(49):7281-9. PubMed ID: 16027731
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive profiling of 8p11-12 amplification in breast cancer.
Gelsi-Boyer V; Orsetti B; Cervera N; Finetti P; Sircoulomb F; Rougé C; Lasorsa L; Letessier A; Ginestier C; Monville F; Esteyriès S; Adélaïde J; Esterni B; Henry C; Ethier SP; Bibeau F; Mozziconacci MJ; Charafe-Jauffret E; Jacquemier J; Bertucci F; Birnbaum D; Theillet C; Chaffanet M
Mol Cancer Res; 2005 Dec; 3(12):655-67. PubMed ID: 16380503
[TBL] [Abstract][Full Text] [Related]
3. gamma-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line.
Wang XZ; Jolicoeur EM; Conte N; Chaffanet M; Zhang Y; Mozziconacci MJ; Feiner H; Birnbaum D; Pébusque MJ; Ron D
Oncogene; 1999 Oct; 18(41):5718-21. PubMed ID: 10523851
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
Wiseman SM; Makretsov N; Nielsen TO; Gilks B; Yorida E; Cheang M; Turbin D; Gelmon K; Huntsman DG
Cancer; 2005 May; 103(9):1770-7. PubMed ID: 15770691
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
6. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization.
Somiari SB; Shriver CD; He J; Parikh K; Jordan R; Hooke J; Hu H; Deyarmin B; Lubert S; Malicki L; Heckman C; Somiari RI
Cancer Genet Cytogenet; 2004 Dec; 155(2):108-18. PubMed ID: 15571796
[TBL] [Abstract][Full Text] [Related]
7. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features.
Shibata T; Uryu S; Kokubu A; Hosoda F; Ohki M; Sakiyama T; Matsuno Y; Tsuchiya R; Kanai Y; Kondo T; Imoto I; Inazawa J; Hirohashi S
Clin Cancer Res; 2005 Sep; 11(17):6177-85. PubMed ID: 16144918
[TBL] [Abstract][Full Text] [Related]
8. MYB oncogene amplification in hereditary BRCA1 breast cancer.
Kauraniemi P; Hedenfalk I; Persson K; Duggan DJ; Tanner M; Johannsson O; Olsson H; Trent JM; Isola J; Borg A
Cancer Res; 2000 Oct; 60(19):5323-8. PubMed ID: 11034064
[TBL] [Abstract][Full Text] [Related]
9. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
10. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
11. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Adélaïde J; Huang HE; Murati A; Alsop AE; Orsetti B; Mozziconacci MJ; Popovici C; Ginestier C; Letessier A; Basset C; Courtay-Cahen C; Jacquemier J; Theillet C; Birnbaum D; Edwards PA; Chaffanet M
Genes Chromosomes Cancer; 2003 Aug; 37(4):333-45. PubMed ID: 12800145
[TBL] [Abstract][Full Text] [Related]
12. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes.
Garcia MJ; Pole JC; Chin SF; Teschendorff A; Naderi A; Ozdag H; Vias M; Kranjac T; Subkhankulova T; Paish C; Ellis I; Brenton JD; Edwards PA; Caldas C
Oncogene; 2005 Aug; 24(33):5235-45. PubMed ID: 15897872
[TBL] [Abstract][Full Text] [Related]
13. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
14. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
15. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.
Kauraniemi P; Bärlund M; Monni O; Kallioniemi A
Cancer Res; 2001 Nov; 61(22):8235-40. PubMed ID: 11719455
[TBL] [Abstract][Full Text] [Related]
16. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
17. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
18. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
19. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
20. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
